ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.2 | 0.2 | 0.0 |
| Other income | 0.1 | 0.0 | 0.3 |
| Total income | 1.2 | 0.2 | 0.3 |
| Profit before exceptional items & tax | 0.6 | -0.3 | 0.2 |
| Profit before tax | 0.6 | -0.3 | 0.2 |
| Net profit | 0.5 | -0.3 | 0.2 |
| Operating margin | 50.0% | -150.0% | 66.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +150.00% |
|---|
BSE results filing, BSE: 534920. Figures extracted from the filing.
Covidh Technologies Ltd: key numbers
- Share price
- ₹143.90
- Market cap
- ₹121.0 Cr
- Revenue (annual)
- ₹1.36 Cr
- Net profit (annual)
- ₹0.26 Cr
- P/E (TTM)
- 466.5×Sector 23.6×
- Promoter holding
- 55.07%-3.56% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Covidh Technologies Ltd
All →iSERA Lifesciences Other Announcement
iSERA Lifesciences will not comply with Regulation 23(9) for the half year ended 30 September 2026. Its capital and net worth are below exemption thresholds.
iSERA Lifesciences Q2 FY27 Results: Net Loss of ₹0.1 Cr
iSERA Lifesciences Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.1 Cr
iSERA Lifesciences Board Meeting Date
iSERA Lifesciences gave notice of a board meeting on November 4, 2026 to consider standalone unaudited results for the quarter and half year ended September 30, 2026. The filing also notes the trading window closure from October 1, 2026.
iSERA Lifesciences Other Announcement
iSERA Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
iSERA Lifesciences Capital Structure Change
Promoters and directors of iSERA Lifesciences acquired shares through a preferential offer valued at ₹113.98 Crore. This transaction changes the company's capital structure.
- Value
- ₹114.0 Cr
iSERA Lifesciences Capital Structure Change
Promoter Pratap Dadasaheb Deshmukh acquired 86.13 lakh shares via preferential allotment. His stake in iSERA Lifesciences shifted to 55.07% following the company's capital restructuring.